2026 Southeastern Residency Conference

The purpose of this study was to evaluate the effect of a pharmacist-led transitions of care (TOC) consult service, specifically designed to address medication access barriers, on patients undergoing inpatient percutaneous coronary interventions. The study sought to assess the program’s impact on medication adherence and hospital readmission rates at 30- and 90-days post-discharge, while also contextualizing these outcomes within the existing body of literature. This retrospective study evaluated the impact of pharmacist-led interventions during TOC consults on medication adherence and hospital readmission. The study period extended from April 1, 2023, through April 1, 2025, providing a two-year window to ensure adequate patient capture. Data were extracted from the electronic health record and entered into REDCap, with all protected health information excluded to maintain confidentiality and compliance with institutional review standards. The primary outcome was the first-fill rate of antiplatelet medications among patients admitted under the post–coronary artery stent pathway who underwent percutaneous coronary intervention during their inpatient stay at this academic medical center, assessing whether pharmacist engagement improved timely medication initiation in a population at elevated cardiovascular risk. Secondary outcomes included 30-day and 90-day readmission rates, documentation of pharmacist clinical interventions across inpatient and outpatient settings, and the type of medication access support provided to patients who filled their antiplatelet prescriptions at the hospital’s affiliated outpatient pharmacy at discharge, providing additional insight into the broader impact of pharmacist involvement during care transitions. The primary endpoint was analyzed using a chi-square test, and descriptive and inferential statistics were applied to secondary outcomes as appropriate. Collectively, this study aimed to characterize the role of pharmacists in optimizing medication use, reducing readmissions, and improving outcomes for patients undergoing percutaneous coronary intervention.